Welcome to our dedicated page for Axcelis Technologies news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Technologies stock.
Axcelis Technologies Inc. (Nasdaq: ACLS) is a world-leading provider of equipment and services to the semiconductor manufacturing industry. For over 35 years, Axcelis has been a trusted partner for chipmakers globally, delivering cutting-edge solutions and expertise in the critical process of ion implantation. This process is essential for the fabrication of semiconductor chips used in everyday electronics such as smartphones, laptops, cameras, and more.
The company's suite of products includes advanced ion implantation systems, which form transistors that power electronic devices. Axcelis' Purion™ platform is renowned for its flexibility and advanced technology, catering to diverse needs from high current to high energy implants. The Purion Power Series™, particularly, addresses the growing demand in power device applications, including silicon carbide (SiC) technology, crucial for automotive, industrial, and energy applications.
Axcelis also offers comprehensive aftermarket services, including spare parts, equipment upgrades, maintenance, and customer training, ensuring maximum operational efficiency and longevity of its products. The company’s advanced technology center in Beverly, Mass., serves as a hub for innovation, collaborating with industry experts and customers to develop next-generation applications.
Financially robust, Axcelis continues to achieve record performance. In 2023, the company reported a 23% year-over-year growth, with revenues surpassing $1.1 billion. The strong market position is further evidenced by a $1.2 billion backlog at the year's end. Axcelis' strategic focus on the Asia Pacific region, which contributes significantly to its revenue, underscores its global outreach and market adaptability.
Recent achievements highlight Axcelis' leadership and innovation. The company showcased its latest technologies at SEMICON Korea 2024 and announced multiple shipments of its Purion Power Series™ to leading chipmakers worldwide. Axcelis also strengthened its board with new directors, bringing in valuable industry expertise.
As the semiconductor industry evolves, Axcelis remains committed to driving innovation and supporting its customers with state-of-the-art ion implantation solutions, ensuring a bright and technologically advanced future.
Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has announced its participation in two upcoming investor conferences. The company will attend the 2024 Wells Fargo TMT Summit at the Terranea Resort in Rancho Palos Verdes on December 3-4, 2024, where management will conduct one-on-one investor meetings. Additionally, Axcelis will participate in the 13th Annual NYC Summit at Mastro's New York on December 17, 2024, hosting small group meetings. The NYC Summit is invitation-only, restricted to accredited investors and publishing research analysts.
Axcelis Technologies (NASDAQ: ACLS) reported Q3 2024 financial results with revenue of $256.6 million, slightly up from $256.5 million in Q2. Operating profit decreased to $46.9 million from $52.8 million, while net income fell to $48.6 million ($1.49 per diluted share) from $50.9 million ($1.55 per share). Gross margin declined to 42.9% from 43.8%. The company expects Q4 2024 revenues of approximately $245 million with EPS of $1.25. Additionally, Axcelis corrected historical backlog figures, with Q2 2024 backlog revised to $879 million from previously reported $994 million. Q3 2024 backlog stands at $758 million.
Axcelis Technologies (Nasdaq: ACLS), a leading supplier of ion implantation solutions for the semiconductor industry, has announced the timing for its third quarter 2024 financial results. The company will release its Q3 2024 results on Wednesday, November 6, 2024, at 4:00 p.m. ET.
Following the release, Axcelis will host a conference call to discuss the results on Thursday, November 7, 2024, at 8:30 a.m. ET. Investors and interested parties can access the call via a webcast through the Investors page of Axcelis' website or by registering as a participant through a provided link. The webcast replay will be available for 30 days after the call.
Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of ion implantation solutions for the semiconductor industry, has announced its participation in the International Conference on Silicon Carbide and Related Materials (ICSCRM 2024). The event will take place from September 29 to October 4, 2024, at the Raleigh Convention Center in North Carolina. Axcelis' management will be available for one-on-one meetings during the conference.
Dr. Russell Low, President and CEO of Axcelis, expressed excitement about participating in ICSCRM 2024, describing it as one of the most important technology forums in the power market. He highlighted the company's Purion™ Power Series as the technology leader in this market, citing its enabling and highly differentiated features and process control. Dr. Low also emphasized the critical role of ion implant in manufacturing Silicon Carbide devices, a market estimated by Yole to grow at a 25% CAGR from 2023 to 2029.
Axcelis Technologies (NASDAQ: ACLS) announced its Platinum Sponsorship of the International Conference on Ion Implantation Technology 2024 (IIT 2024) in Toyama, Japan. The event, scheduled for September 23-26, focuses on challenges in implant/doping and annealing processes, device applications, equipment, metrology, and modeling. Axcelis will host an exhibit and present nine topics, including performance of aluminum sputtering sources, energetic metals characterization, radiation mitigation, and innovations in wide bandgap materials.
CEO Russell Low emphasized the importance of the Japanese market for Axcelis, noting recent openings of new Service Centers in Japan. The company aims to grow its global market share by providing innovative implant technology and support solutions.
Axcelis Technologies (Nasdaq: ACLS) announced its participation in the inaugural SEMICON India 2024, showcasing its Purion™ and GSD Ovation™ Series of ion implanters. The event will be held from September 11-13 at the India Expo Mart in Greater Noida, Delhi. Axcelis will exhibit in Booth #H1T11, featuring innovative ion implant solutions that offer significant technology and manufacturing advantages.
The showcase includes the Purion Power Series™ for thin silicon, TAIKO, and SiC wafer processing; the Purion H Series for high current implants; the Purion XE Series for high energy implants; and the GSD Ovation™ for cost-effective batch platform capability. CEO Russell Low highlighted the importance of the Indian semiconductor market, projected to reach over $55 billion by 2026, driven by smartphones, automotive components, and computing sectors.
Axcelis Technologies (NASDAQ: ACLS), a key player in ion implantation solutions for the semiconductor industry, announced its participation in several upcoming investor conferences.
August 22nd: 5th Annual Needham Virtual Semiconductor & SemiCap 1x1 Conference.
August 27th: Jefferies Semiconductor, IT Hardware, Communications Software and Infrastructure Summit at the Four Seasons Hotel, Chicago, IL.
August 28th: Evercore ISI 2024 Semiconductor, IT Hardware & Networking Conference at the Omni Chicago.
September 4th: Benchmark 2024 Tech/Media/Telecom Conference at the New York Athletic Club.
September 12th: B. Riley Securities Consumer & TMT Conference at the Sofitel, New York.
Management will be available for one-on-ones and small group meetings at these events.
Axcelis Technologies (NASDAQ: ACLS) reported strong Q2 2024 financial results, with revenue of $256.5 million, up from $252.4 million in Q1. The company's operating margin was 20.6%, with diluted EPS of $1.55. Gross margin decreased slightly to 43.8% from 46.0% in Q1. CEO Russell Low highlighted better-than-expected conversion of evaluation units and robust demand in the Power segment, particularly in silicon carbide. For Q3 2024, Axcelis expects revenues of approximately $255 million and EPS of about $1.43. The company anticipates revenue in the second half of 2024 to be slightly better than the first half, with momentum building into 2025.
Axcelis Technologies (Nasdaq: ACLS), a leading supplier of ion implantation solutions for the semiconductor industry, has announced the timing for its second quarter 2024 financial results. The company will release its Q2 2024 results on Wednesday, July 31, 2024, at 4:00 p.m. ET. Following this, Axcelis will host a conference call to discuss these results on Thursday, August 1, 2024, at 8:30 a.m. ET.
Interested parties can access the call via an audio webcast on the Investors page of Axcelis' website or by registering as a participant through a provided link. The webcast replay will be available for 30 days after the call.
Axcelis Technologies, a key supplier in the semiconductor industry, announced preliminary Q2 2024 financial results ahead of an investor event. The company expects revenue to surpass $252 million, exceeding prior guidance of $245 million. Diluted earnings per share (EPS) are anticipated to be over $1.38, compared to the previous estimate of $1.30. CEO Russell Low attributed the strong performance to robust demand for the Purion platform. Axcelis projects a stronger second half of 2024, with a slight emphasis on Q4. Final Q2 results will be released on July 31, 2024.
FAQ
What is the current stock price of Axcelis Technologies (ACLS)?
What is the market cap of Axcelis Technologies (ACLS)?
What does Axcelis Technologies Inc. specialize in?
What are the key products of Axcelis Technologies?
How does Axcelis support its products post-sale?
Where is Axcelis Technologies headquartered?
What financial achievements did Axcelis report for 2023?
What is the significance of the Purion Power Series™?
How does Axcelis collaborate with the semiconductor industry?
What recent strategic moves has Axcelis made?
What upcoming events is Axcelis participating in?
What is the future outlook for Axcelis Technologies?
